Research programme: growth arrest specific gene 6 inhibitors - ThromboGenics

Drug Profile

Research programme: growth arrest specific gene 6 inhibitors - ThromboGenics

Alternative Names: Gas6 inhibitors research programme - ThromboGenics; Growth arrest specific gene 6 inhibitors research programme - ThromboGenics

Latest Information Update: 04 Jan 2007

Price : $50

At a glance

  • Originator University of Leuven
  • Developer Thromb-X; ThromboGenics
  • Class
  • Mechanism of Action Growth arrest-specific protein 6 inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 04 Jun 2003 This programme is still in active development
  • 22 May 2001 New profile
  • 22 May 2001 Preclinical development for Arterial thrombosis in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top